| Objectives: To evaluate the efficacy and safety of intracoronary tirofiban during primary percutaneous coronary intervention(PPCI) for patients with ST-segment Elevation Myocardial Infarction(STEMI).Methods:From January 2013 to June 2014, 30 patients with STEMI who underwent PPCI intra-infarction related artery tirofiban, then with subsequent 24-hour intravenous infusion after angioplasty(tirofiban group) and 31 matched control patients with STEMI who just underwent angioplasty(Simple stent group). Collect this clinical data: The age, body mass index(BMI), heart rate, blood pressure, cholesterol, blood sugar immediately hospitalized, the Computer-Assisted Myocardial Blush Quantification(Qu BE sore) after angioplasty, the left ventricular fraction(LVEF) in the hospital and at 6 month follow-up, major adverse cardiac events(MACE) and so on.Results: The baseline characteristics of the two group were well-balanced. The Qu BE score and LVEF in 6-month(P=0.014;P=0.045) was significantly higher in the tirofiban group than in the simple stent group. A positive correlation between Qu BE and LVEF% was found(y=0.502x+49.794,P=0.009) with linear regression analysis. There was a tendency to decreased MACE at 6-month follow-up,which triofiban group(χ2=5.599,P=0.018).Conclusion: Intracoronary Tirofiban in patients with STEMI undergoing PPCI may improve the myocardium perfusion and result in a better clinical prognosis.The people could not only use the Qu BE to assess the myocardial microcirculation about the STEMI with the coronary intervention timely and accurately, but also forecast the short-term preognosis.
|
PDF Full Text Request